New findings indicate that patients with psoriasis treated with phototherapy have a higher risk of developing non-melanoma skin cancers (NMSCs) compared with those receiving anti-tumor necrosis factor α (TNFα) agents. Led by Emanuele Researchers of the study evaluated 200 adults with a 6-year history of psoriasis, dividing them into two groups: 100 received narrow-band UVB phototherapy and 100 were treated with adalimumab. Over a 5-year period, 34 participants in the phototherapy group developed NMSCs, while none in the adalimumab group did.

The results highlight the need for careful monitoring of patients with psoriasis, especially those undergoing phototherapy, for potential skin cancer development. The research underscores the importance of considering treatment types, patient age, and anatomical locations in assessing NMSC risk. Despite similar obesity rates between the cohorts, the increased NMSC incidence in the phototherapy group suggests a significant risk factor that warrants further investigation. This study provides valuable insights into the relationship between psoriasis treatments and skin cancer risk, emphasizing the need for more precise understanding and management strategies.

Reference: Smith T. Skin Cancer More Likely Among Psoriasis Patients Treated with Phototherapy Versus Adalimumab. HCPLive. Published May 23, 2024. Accessed June 18, 2024. https://www.hcplive.com/view/skin-cancer-more-likely-among-psoriasis-patients-treated-with-phototherapy-versus-adalimumab